|
1
|
Shimabukuro-Vornhagen A, Böll B,
Schellongowski P, Valade S, Metaxa V, Azoulay E and von
Bergwelt-Baildon M: Critical care management of chimeric antigen
receptor T-cell therapy recipients. CA Cancer J Clin. 72:78–93.
2022. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Lin H, Cheng J, Mu W, Zhou J and Zhu L:
Advances in universal CAR-T cell therapy. Front Immunol.
12:7448232021. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Cameron BJ, Gerry AB, Dukes J, Harper JV,
Kannan V, Bianchi FC, Grand F, Brewer JE, Gupta M, Plesa G, et al:
Identification of a Titin-derived HLA-A1-presented peptide as a
cross-reactive target for engineered MAGE A3-directed T cells. Sci
Transl Med. 5:197ra1032013. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Morgan RA, Yang JC, Kitano M, Dudley ME,
Laurencot CM and Rosenberg SA: Case report of a serious adverse
event following the administration of T cells transduced with a
chimeric antigen receptor recognizing ERBB2. Mol Ther. 18:843–851.
2010. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Brudno JN and Kochenderfer JN: Toxicities
of chimeric antigen receptor T cells: Recognition and management.
Blood. 127:3321–3330. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Owusu KA, Schiffer M and Perreault S:
Chimeric antigen receptor T cells: Toxicity and management
considerations. AACN Adv Crit Care. 33:301–307. 2022. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Freyer CW and Porter DL: Cytokine release
syndrome and neurotoxicity following CAR T-cell therapy for
hematologic malignancies. J Allergy Clin Immunol. 146:940–948.
2020. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Major A, Collins J, Craney C, Heitman AK,
Bauer E, Zerante E, Stock W, Bishop MR and Jasielec J: Management
of hemophagocytic lymphohistiocytosis (HLH) associated with
chimeric antigen receptor T-cell (CAR-T) therapy using
anti-cytokine therapy: An illustrative case and review of the
literature. Leuk Lymphoma. 62:1765–1769. 2021. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Hines MR, Knight TE, McNerney KO, Leick
MB, Jain T, Ahmed S, Frigault MJ, Hill JA, Jain MD, Johnson WT, et
al: Immune effector cell-associated hemophagocytic
lymphohistiocytosis-like syndrome. Transplant Cell Ther.
29:438.e1–438.e16. 2023. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Sandler RD, Tattersall RS, Schoemans H,
Greco R, Badoglio M, Labopin M, Alexander T, Kirgizov K, Rovira M,
Saif M, et al: Diagnosis and management of secondary HLH/MAS
following HSCT and CAR-T cell therapy in adults; A review of the
literature and a survey of practice within EBMT centres on behalf
of the autoimmune diseases working party (ADWP) and transplant
complications working party (TCWP). Front Immunol. 11:5242020.
View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Lichtenstein DA, Schischlik F, Shao L,
Steinberg SM, Yates B, Wang HW, Wang Y, Inglefield J, Dulau-Florea
A, Ceppi F, et al: Characterization of HLH-like manifestations as a
CRS variant in patients receiving CD22 CAR T cells. Blood.
138:2469–2484. 2021. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Hines MR, Keenan C, Maron Alfaro G, Cheng
C, Zhou Y, Sharma A, Hurley C, Nichols KE, Gottschalk S, Triplett
BM and Talleur AC: Hemophagocytic lymphohistiocytosis-like toxicity
(carHLH) after CD19-specific CAR T-cell therapy. Br J Haematol.
194:701–707. 2021. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Shah NN, Highfill SL, Shalabi H, Yates B,
Jin J, Wolters PL, Ombrello A, Steinberg SM, Martin S, Delbrook C,
et al: CD4/CD8 T-cell selection affects chimeric antigen receptor
(CAR) T-cell potency and toxicity: updated results from a phase I
anti-CD22 CAR T-cell trial. J Clin Oncol. 38:1938–1950. 2020.
View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Debaugnies F, Mahadeb B, Ferster A,
Meuleman N, Rozen L, Demulder A and Corazza F: Performances of the
H-score for diagnosis of hemophagocytic lymphohistiocytosis in
adult and pediatric patients. Am J Clin Pathol. 145:862–870. 2016.
View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Schubert ML, Schmitt M, Wang L, Ramos CA,
Jordan K, Müller-Tidow C and Dreger P: Side-effect management of
chimeric antigen receptor (CAR) T-cell therapy. Ann Oncol.
32:34–48. 2021. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Hayden PJ, Roddie C, Bader P, Basak GW,
Bonig H, Bonini C, Chabannon C, Ciceri F, Corbacioglu S, Ellard R,
et al: Management of adults and children receiving CAR T-cell
therapy: 2021 Best practice recommendations of the European society
for blood and marrow transplantation (EBMT) and the joint
accreditation committee of ISCT and EBMT (JACIE) and the European
haematology association (EHA). Ann Oncol. 33:259–275. 2022.
View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Ponnatt TS, Lilley CM and Mirza KM:
Hemophagocytic lymphohistiocytosis. Arch Pathol Lab Med.
146:507–519. 2022. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Schram AM, Comstock P, Campo M, Gorovets
D, Mullally A, Bodio K, Arnason J and Berliner N: Haemophagocytic
lymphohistiocytosis in adults: A multicentre case series over 7
years. Br J Haematol. 172:412–419. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Henter JI: Hemophagocytic
lymphohistiocytosis. N Engl J Med. 392:584–598. 2025. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Henter JI, Elinder G, Söder O and Ost A:
Incidence in Sweden and clinical features of familial
hemophagocytic lymphohistiocytosis. Acta Paediatr Scand.
80:428–435. 1991. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Ravelli A, Minoia F, Davi S, Horne A,
Bovis F, Pistorio A, Aricò M, Avcin T, Behrens EM, De Benedetti F,
et al: 2016 Classification criteria for macrophage activation
syndrome complicating systemic juvenile idiopathic arthritis: A
European league against rheumatism/American college of
rheumatology/paediatric rheumatology international trials
organisation collaborative initiative. Ann Rheum Dis. 75:481–489.
2016. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Ramos-Casals M, Brito-Zerón P,
López-Guillermo A, Khamashta MA and Bosch X: Adult haemophagocytic
syndrome. Lancet. 383:1503–1516. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
He L, Yang C and Wang Y: Biological
therapies for hemophagocytic lymphohistiocytosis: Current knowledge
and future perspectives. Expert Opin Biol Ther. 23:1005–1013. 2023.
View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Janka GE and Lehmberg K: Hemophagocytic
syndromes-an update. Blood Rev. 28:135–142. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Griffin G, Shenoi S and Hughes GC:
Hemophagocytic lymphohistiocytosis: An update on pathogenesis,
diagnosis, and therapy. Best Pract Res Clin Rheumatol.
34:1015152020. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Filipovich A, McClain K and Grom A:
Histiocytic disorders: Recent insights into pathophysiology and
practical guidelines. Biol Blood Marrow Transplant. 16 (1
Suppl):S82–S89. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Arceci RJ: When T cells and macrophages do
not talk: The hemophagocytic syndromes. Curr Opin Hematol.
15:359–367. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Niece JA, Rogers ZR, Ahmad N, Langevin AM
and McClain KL: Hemophagocytic lymphohistiocytosis in Texas:
Observations on ethnicity and race. Pediatr Blood Cancer.
54:424–428. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Löfstedt A, Jädersten M, Meeths M and
Henter JI: Malignancy-associated hemophagocytic lymphohistiocytosis
in Sweden: Incidence, clinical characteristics, and survival.
Blood. 143:233–242. 2024. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Singh S, Khasbage S, Kaur RJ, Sidhu JK and
Bhandari B: Chimeric antigen receptor T cell: A cancer
immunotherapy. Indian J Pharmacol. 54:226–233. 2022. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Chong EA, Ruella M and Schuster SJ;
Lymphoma Program Investigators at the University of Pennsylvania, :
Five-year outcomes for refractory B-cell lymphomas with CAR T-cell
therapy. N Engl J Med. 384:673–674. 2021. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Maude SL, Frey N, Shaw PA, Aplenc R,
Barrett DM, Bunin NJ, Chew A, Gonzalez VE, Zheng Z, Lacey SF, et
al: Chimeric antigen receptor T cells for sustained remissions in
leukemia. N Engl J Med. 371:1507–1517. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Cappell KM, Sherry RM, Yang JC, Goff SL,
Vanasse DA, McIntyre L, Rosenberg SA and Kochenderfer JN: Long-term
follow-up of anti-CD19 chimeric antigen receptor T-cell therapy. J
Clin Oncol. 38:3805–3815. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Feins S, Kong W, Williams EF, Milone MC
and Fraietta JA: An introduction to chimeric antigen receptor (CAR)
T-cell immunotherapy for human cancer. Am J Hematol. 94((S1)):
S3–S9. 2019.PubMed/NCBI
|
|
35
|
Stone JD and Kranz DM: Role of T cell
receptor affinity in the efficacy and specificity of adoptive T
cell therapies. Front Immunol. 4:2442013. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Berdeja JG, Madduri D, Usmani SZ,
Jakubowiak A, Agha M, Cohen AD, Stewart AK, Hari P, Htut M,
Lesokhin A, et al: Ciltacabtagene autoleucel, a B-cell maturation
antigen-directed chimeric antigen receptor T-cell therapy in
patients with relapsed or refractory multiple myeloma
(CARTITUDE-1): A phase 1b/2 open-label study: A phase 1b/2
open-label study. Lancet. 398:314–324. 2021. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Wang T, Tang Y, Cai J, Wan X, Hu S, Lu X,
Xie Z, Qiao X, Jiang H, Shao J, et al: Coadministration of CD19-
and CD22-directed chimeric antigen receptor T-cell therapy in
childhood B-cell acute lymphoblastic leukemia: A single-arm,
multicenter, phase II trial. J Clin Oncol. 41:1670–1683. 2023.
View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Neelapu SS, Locke FL, Bartlett NL, Lekakis
LJ, Miklos DB, Jacobson CA, Braunschweig I, Oluwole OO, Siddiqi T,
Lin Y, et al: Axicabtagene ciloleucel CAR T-cell therapy in
refractory large B-cell lymphoma. N Engl J Med. 377:2531–2544.
2017. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Schuster SJ, Bishop MR, Tam CS, Waller EK,
Borchmann P, McGuirk JP, Jäger U, Jaglowski S, Andreadis C, Westin
JR, et al: Tisagenlecleucel in adult relapsed or refractory diffuse
large B-cell lymphoma. N Engl J Med. 380:45–56. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Frey NV, Shaw PA, Hexner EO, Pequignot E,
Gill S, Luger SM, Mangan JK, Loren AW, Perl AE, Maude SL, et al:
Optimizing chimeric antigen receptor T-cell therapy for adults with
acute lymphoblastic leukemia. J Clin Oncol. 38:415–422. 2020.
View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Raje N, Berdeja J, Lin Y, Siegel D,
Jagannath S, Madduri D, Liedtke M, Rosenblatt J, Maus MV, Turka A,
et al: Anti-BCMA CAR T-cell therapy bb2121 in relapsed or
refractory multiple myeloma. N Engl J Med. 380:1726–1737. 2019.
View Article : Google Scholar : PubMed/NCBI
|
|
42
|
Bupha-Intr O, Haeusler G, Chee L, Thursky
K, Slavin M and Teh B: CAR-T cell therapy and infection: A review.
Expert Rev Anti Infect Ther. 19:749–758. 2021. View Article : Google Scholar : PubMed/NCBI
|
|
43
|
Lei W, Xie M, Jiang Q, Xu N, Li P, Liang
A, Young KH and Qian W: Treatment-related adverse events of
chimeric antigen receptor T-cell (CAR T) in clinical trials: A
systematic review and meta-analysis. Cancers (Basel). 13:39122021.
View Article : Google Scholar : PubMed/NCBI
|
|
44
|
Zu C, Wu S, Zhang M, Wei G, Xu H, Cui J,
Chang AH, Huang H and Hu Y: A distinct cytokine network
distinguishes chimeric antigen receptor T cell (CAR-T)-associated
hemophagocytic lymphohistiocytosis-like toxicity (carHLH) from
severe cytokine release syndrome following CAR-T therapy.
Cytotherapy. 25:1167–1175. 2023. View Article : Google Scholar : PubMed/NCBI
|
|
45
|
Liu Y, Fang Y, Chen X, Wang Z, Liang X,
Zhang T, Liu M, Zhou N, Lv J, Tang K, et al: Gasdermin E-mediated
target cell pyroptosis by CAR T cells triggers cytokine release
syndrome. Sci Immunol. 5:eaax79692020. View Article : Google Scholar : PubMed/NCBI
|
|
46
|
Maude SL, Laetsch TW, Buechner J, Rives S,
Boyer M, Bittencourt H, Bader P, Verneris MR, Stefanski HE, Myers
GD, et al: Tisagenlecleucel in children and young adults with
B-cell lymphoblastic leukemia. N Engl J Med. 378:439–448. 2018.
View Article : Google Scholar : PubMed/NCBI
|
|
47
|
Brudno JN and Kochenderfer JN: Current
understanding and management of CAR T cell-associated toxicities.
Nat Rev Clin Oncol. 21:501–521. 2024. View Article : Google Scholar : PubMed/NCBI
|
|
48
|
Neelapu SS, Tummala S, Kebriaei P, Wierda
W, Gutierrez C, Locke FL, Komanduri KV, Lin Y, Jain N, Daver N, et
al: Chimeric antigen receptor T-cell therapy-assessment and
management of toxicities. Nat Rev Clin Oncol. 15:47–62. 2018.
View Article : Google Scholar : PubMed/NCBI
|
|
49
|
Fajgenbaum DC and June CH: Cytokine storm.
N Engl J Med. 383:2255–2273. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
50
|
Yan W, Xiong Y, Lv R, Du C, Yu T, Zhang S,
Sui W, Deng S, Xiao J, Xu Y, et al: Uncommon biphasic CAR-T
expansion induces hemophagocytic lymphohistiocytosis-like syndrome
and fatal multiple infections following BCMA CAR-T cell therapy: A
case report. J Immunother Cancer. 12:e0100802024. View Article : Google Scholar : PubMed/NCBI
|
|
51
|
Vandenhaute J, Wouters CH and Matthys P:
Natural killer cells in systemic autoinflammatory diseases: A focus
on systemic juvenile idiopathic arthritis and macrophage activation
syndrome. Front Immunol. 10:30892020. View Article : Google Scholar : PubMed/NCBI
|
|
52
|
Weiss ES, Girard-Guyonvarc'h C, Holzinger
D, de Jesus AA, Tariq Z, Picarsic J, Schiffrin EJ, Foell D, Grom
AA, Ammann S, et al: Interleukin-18 diagnostically distinguishes
and pathogenically promotes human and murine macrophage activation
syndrome. Blood. 131:1442–1455. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
53
|
Kaplanski G: Interleukin-18: Biological
properties and role in disease pathogenesis. Immunol Rev.
281:138–153. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
54
|
Miao L, Zhang Z, Ren Z and Li Y: Reactions
related to CAR-T cell therapy. Front Immunol. 12:6632012021.
View Article : Google Scholar : PubMed/NCBI
|
|
55
|
Nichols KE and Hines MR: NK cells:
Energized yet exhausted in adult HLH. Blood. 136:524–525. 2020.
View Article : Google Scholar : PubMed/NCBI
|
|
56
|
Strati P, Ahmed S, Kebriaei P, Nastoupil
LJ, Claussen CM, Watson G, Horowitz SB, Brown ART, Do B, Rodriguez
MA, et al: Clinical efficacy of anakinra to mitigate CAR T-cell
therapy-associated toxicity in large B-cell lymphoma. Blood Adv.
4:3123–3127. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
57
|
Ahmed S, Furqan F, Strati P, Westin J,
Fayad LE, Hagemeister FB, Lee HJ, Iyer SP, Nair R, Nastoupil LJ, et
al: Haemophagocytic lymphohistiocytosis (HLH) in patients with
large B-cell lymphoma treated with standard of care (SOC)
axicabtagene ciloleucel (Axi-cel). J Clin Oncol. 38 (15
Suppl):S80572020. View Article : Google Scholar
|
|
58
|
Lee DW, Santomasso BD, Locke FL, Ghobadi
A, Turtle CJ, Brudno JN, Maus MV, Park JH, Mead E, Pavletic S, et
al: ASTCT consensus grading for cytokine release syndrome and
neurologic toxicity associated with immune effector cells. Biol
Blood Marrow Transplant. 25:625–638. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
59
|
Meireles AM, Iacoboni G, Moço LM, Ramos I,
Brás G, Azevedo J, Rodrigues Â, Moreira C and Mariz M:
Hemophagocytic lymphohistiocytosis in a patient with Epstein-Barr
virus-positive diffuse large B-cell lymphoma treated with chimeric
antigen receptor T-cell therapy. Immunotherapy. 16:1105–1111. 2024.
View Article : Google Scholar : PubMed/NCBI
|
|
60
|
Khurana A, Rosenthal AC, Mohty R, Gaddam
M, Bansal R, Hathcock MA, Nedved AN, Durani U, Iqbal M, Wang Y, et
al: Chimeric antigen receptor T-cell therapy associated
hemophagocytic lymphohistiocytosis syndrome: Clinical presentation,
outcomes, and management. Blood Cancer J. 14:1362024. View Article : Google Scholar : PubMed/NCBI
|
|
61
|
Henter JI, Horne A, Aricó M, Egeler RM,
Filipovich AH, Imashuku S, Ladisch S, McClain K, Webb D, Winiarski
J and Janka G: HLH-2004: Diagnostic and therapeutic guidelines for
hemophagocytic lymphohistiocytosis. Pediatr Blood Cancer.
48:124–131. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
62
|
Fardet L, Galicier L, Lambotte O, Marzac
C, Aumont C, Chahwan D, Coppo P and Hejblum G: Development and
validation of the HScore, a score for the diagnosis of reactive
hemophagocytic syndrome. Arthritis Rheumatol. 66:2613–2620. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
63
|
Takagi S, Masuoka K, Uchida N, Ishiwata K,
Araoka H, Tsuji M, Yamamoto H, Kato D, Matsuhashi Y, Kusumi E, et
al: High incidence of haemophagocytic syndrome following umbilical
cord blood transplantation for adults. Br J Haematol. 147:543–553.
2009. View Article : Google Scholar : PubMed/NCBI
|
|
64
|
Porter TJ, Lazarevic A, Ziggas JE, Fuchs
E, Kim K, Byrnes H, Luznik L, Bolaños-Meade J, Ali SA, Shah NN, et
al: Hyperinflammatory syndrome resembling haemophagocytic
lymphohistiocytosis following axicabtagene ciloleucel and
brexucabtagene autoleucel. Br J Haematol. 199:720–727. 2022.
View Article : Google Scholar : PubMed/NCBI
|
|
65
|
Turtle CJ, Hanafi LA, Berger C, Hudecek M,
Pender B, Robinson E, Hawkins R, Chaney C, Cherian S, Chen X, et
al: Immunotherapy of non-Hodgkin's lymphoma with a defined ratio of
CD8+ and CD4+ CD19-specific chimeric antigen receptor-modified T
cells. Sci Transl Med. 8:355ra1162016. View Article : Google Scholar : PubMed/NCBI
|
|
66
|
Zhang Y, Zhou F, Wu Z, Li Y, Li C, Du M,
Luo W, Kou H, Lu C and Mei H: Timing of tocilizumab administration
under the guidance of IL-6 in CAR-T therapy for R/R acute
lymphoblastic leukemia. Front Immunol. 13:9149592022. View Article : Google Scholar : PubMed/NCBI
|
|
67
|
He J, Xu N, Zhou H, Zhou Y, Wu D, Zhao R,
Lin T, Xu J, Cao R, Li P and Liu Q: Case report: Chimeric antigen
receptor T cells induced late severe cytokine release syndrome.
Front Oncol. 12:8939282022. View Article : Google Scholar : PubMed/NCBI
|
|
68
|
Sigha OB, Mbono Betoko R, Nkoro GA, Fossi
Happi M, Ekoube CE, Kelbaba BB, Mandeng Ma Linwa E and Kouotou EA:
Bart's syndrome associated with a disorder of sexual
differentiation: An atypical presentation in a Cameroonian newborn.
Clin Case Rep. 10:e052342022. View Article : Google Scholar : PubMed/NCBI
|
|
69
|
Maus MV, Alexander S, Bishop MR, Brudno
JN, Callahan C, Davila ML, Diamonte C, Dietrich J, Fitzgerald JC,
Frigault MJ, et al: Society for Immunotherapy of Cancer (SITC)
clinical practice guideline on immune effector cell-related adverse
events. J Immunother Cancer. 8:e0015112020. View Article : Google Scholar : PubMed/NCBI
|
|
70
|
Santomasso BD, Nastoupil LJ, Adkins S,
Lacchetti C, Schneider BJ, Anadkat M, Atkins MB, Brassil KJ,
Caterino JM, Chau I, et al: Management of immune-related adverse
events in patients treated with chimeric antigen receptor T-cell
therapy: ASCO guideline. J Clin Oncol. 39:3978–3992. 2021.
View Article : Google Scholar : PubMed/NCBI
|
|
71
|
Henter JI, Aricò M, Egeler RM, Elinder G,
Favara BE, Filipovich AH, Gadner H, Imashuku S, Janka-Schaub G,
Komp D, et al: HLH-94: A treatment protocol for hemophagocytic
lymphohistiocytosis. HLH study group of the histiocyte society. Med
Pediatr Oncol. 28:342–347. 1997. View Article : Google Scholar : PubMed/NCBI
|
|
72
|
Locatelli F, Jordan MB, Allen C, Cesaro S,
Rizzari C, Rao A, Degar B, Garrington TP, Sevilla J, Putti MC, et
al: Emapalumab in children with primary hemophagocytic
lymphohistiocytosis. N Engl J Med. 382:1811–1822. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
73
|
Ge J, Zhang Q, Ma H, Wang D, Zhao Y, Zhu
T, Wang W, Zhou C, Wei A, Lian H, et al: Ruxolitinib-based regimen
in children with primary hemophagocytic lymphohistiocytosis.
Haematologica. 109:458–465. 2024. View Article : Google Scholar : PubMed/NCBI
|
|
74
|
Rejeski K, Subklewe M, Aljurf M, Bachy E,
Balduzzi A, Barba P, Bruno B, Benjamin R, Carrabba MG, Chabannon C,
et al: Immune effector cell-associated hematotoxicity: EHA/EBMT
consensus grading and best practice recommendations. Blood.
142:865–877. 2023. View Article : Google Scholar : PubMed/NCBI
|
|
75
|
Curtis JR, Westfall AO, Allison J, Bijlsma
JW, Freeman A, George V, Kovac SH, Spettell CM and Saag KG:
Population-based assessment of adverse events associated with
long-term glucocorticoid use. Arthritis Rheum. 55:420–426. 2006.
View Article : Google Scholar : PubMed/NCBI
|
|
76
|
Kim JY, Kim M, Park JK, Lee EB, Park JW
and Hong J: Limited efficacy of tocilizumab in adult patients with
secondary hemophagocytic lymphohistiocytosis: A retrospective
cohort study. Orphanet J Rare Dis. 17:3632022. View Article : Google Scholar : PubMed/NCBI
|
|
77
|
Park JH, Nath K, Devlin SM, Sauter CS,
Palomba ML, Shah G, Dahi P, Lin RJ, Scordo M, Perales MA, et al:
CD19 CAR T-cell therapy and prophylactic anakinra in relapsed or
refractory lymphoma: Phase 2 trial interim results. Nat Med.
29:1710–1717. 2023. View Article : Google Scholar : PubMed/NCBI
|
|
78
|
Wohlfarth P, Agis H, Gualdoni GA, Weber J,
Staudinger T, Schellongowski P and Robak O: Interleukin 1 receptor
antagonist anakinra, intravenous immunoglobulin, and
corticosteroids in the management of critically ill adult patients
with hemophagocytic lymphohistiocytosis. J Intensive Care Med.
34:723–731. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
79
|
Diorio C, Vatsayan A, Talleur AC, Annesley
C, Jaroscak JJ, Shalabi H, Ombrello AK, Hudspeth M, Maude SL,
Gardner RA and Shah NN: Anakinra utilization in refractory
pediatric CAR T-cell associated toxicities. Blood Adv. 6:3398–3403.
2022. View Article : Google Scholar : PubMed/NCBI
|
|
80
|
Abedin S, McKenna E, Chhabra S, Pasquini
M, Shah NN, Jerkins J, Baim A, Runaas L, Longo W, Drobyski W, et
al: Efficacy, toxicity, and infectious complications in
ruxolitinib-treated patients with corticosteroid-refractory
graft-versus-host disease after hematopoietic cell transplantation.
Biol Blood Marrow Transplant. 25:1689–1694. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
81
|
Bracaglia C, de Graaf K, Pires Marafon D,
Guilhot F, Ferlin W, Prencipe G, Caiello I, Davì S, Schulert G,
Ravelli A, et al: Elevated circulating levels of interferon-γ and
interferon-γ-induced chemokines characterise patients with
macrophage activation syndrome complicating systemic juvenile
idiopathic arthritis. Ann Rheum Dis. 76:166–172. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
82
|
Horne A, von Bahr Greenwood T, Chiang SCC,
Meeths M, Björklund C, Ekelund M, Erensjö P, Berg S, Hagelberg S,
Bryceson YT, et al: Efficacy of moderately dosed etoposide in
macrophage activation syndrome-hemophagocytic lymphohistiocytosis.
J Rheumatol. 48:1596–1602. 2021. View Article : Google Scholar : PubMed/NCBI
|
|
83
|
Zondag TCE, Lika A and van Laar JAM: The
role of etoposide in the treatment of adult patients with
hemophagocytic lymphohistiocytosis. Exp Hematol Oncol. 12:22023.
View Article : Google Scholar : PubMed/NCBI
|
|
84
|
Song Y, Wang J, Wang Y, Wu L and Wang Z:
Requirement for containing etoposide in the initial treatment of
lymphoma associated hemophagocytic lymphohistiocytosis. Cancer Biol
Ther. 22:598–606. 2021. View Article : Google Scholar : PubMed/NCBI
|
|
85
|
Henter JI, von Bahr Greenwood T and
Bergsten E: Emapalumab in primary hemophagocytic
lymphohistiocytosis. N Engl J Med. 383:596–598. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
86
|
Bailey SR, Vatsa S, Larson RC, Bouffard
AA, Scarfò I, Kann MC, Berger TR, Leick MB, Wehrli M, Schmidts A,
et al: Blockade or deletion of IFNγ reduces macrophage activation
without compromising CAR T-cell function in hematologic
malignancies. Blood Cancer Discov. 3:136–153. 2022. View Article : Google Scholar : PubMed/NCBI
|
|
87
|
McNerney KO, DiNofia AM, Teachey DT, Grupp
SA and Maude SL: Potential role of IFNγ inhibition in refractory
cytokine release syndrome associated with CAR T-cell therapy. Blood
Cancer Discov. 3:90–94. 2022. View Article : Google Scholar : PubMed/NCBI
|
|
88
|
Verkamp B, Jodele S, Sabulski A, Marsh RA,
Kieser P and Jordan MB: Emapalumab therapy for hemophagocytic
lymphohistiocytosis before reduced-intensity transplantation
improves chimerism. Blood. 144:2625–2636. 2024. View Article : Google Scholar : PubMed/NCBI
|
|
89
|
Garonzi C, Chinello M and Cesaro S:
Emapalumab for adult and pediatric patients with hemophagocytic
lymphohistiocytosis. Expert Rev Clin Pharmacol. 14:527–534. 2021.
View Article : Google Scholar : PubMed/NCBI
|
|
90
|
Wu Y, Sun X, Kang K, Yang Y, Li H, Zhao A
and Niu T: Hemophagocytic lymphohistiocytosis: Current treatment
advances, emerging targeted therapy and underlying mechanisms. J
Hematol Oncol. 17:1062024. View Article : Google Scholar : PubMed/NCBI
|
|
91
|
Roddie C, Lekakis LJ, Marzolini MAV,
Ramakrishnan A, Zhang Y, Hu Y, Peddareddigari VGR, Khokhar N, Chen
R, Basilico S, et al: Dual targeting of CD19 and CD22 with
bicistronic CAR-T cells in patients with relapsed/refractory large
B-cell lymphoma. Blood. 141:2470–2482. 2023.PubMed/NCBI
|
|
92
|
Schultz LM, Jeyakumar N, Kramer AM, Sahaf
B, Srinagesh H, Shiraz P, Agarwal N, Hamilton M, Erickson C, Jacobs
A, et al: CD22 CAR T cells demonstrate high response rates and
safety in pediatric and adult B-ALL: Phase 1b results. Leukemia.
38:963–968. 2024. View Article : Google Scholar : PubMed/NCBI
|
|
93
|
Masih KE, Ligon JA, Yates B, Shalabi H,
Little L, Islam Z, Ombrello AK, Inglefield J, Nussenblatt V, Manion
M, et al: Consequences of hemophagocytic lymphohistiocytosis-like
cytokine release syndrome toxicities and concurrent bacteremia.
Pediatr Blood Cancer. 68:e292472021. View Article : Google Scholar : PubMed/NCBI
|
|
94
|
Service USDoHaH, Health NIo and Institute
NC: National Cancer Institute, . Common terminology criteria for
adverse events (CTCAE). Version 5.0.2017.
|
